Trial Profile

Phase I study of ROC-101 in healthy volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ROC 101 (Primary) ; Fasudil
Indications Interstitial lung diseases; Pulmonary arterial hypertension
Focus Adverse reactions; First in man

Most Recent Events

10 Nov 2025 New trial record
29 Sep 2025 Results presented in the AllRock Bio Media Release.
16 Sep 2025 According to an AllRock Bio media release, latest Phase 1 data will be presented at the European Respiratory Society (ERS) Congress, held September 27-October 1 in Amsterdam

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com